AI-Assisted Insulin Titration System on Inpatients Glucose Control

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System (iNCDSS) in patients with Type 2 Diabetes Mellitus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Men or women aged 18-99 years old;

• Inpatients who had been diagnosed with type 2 diabetes;

• Subjects who are on treatment with insulin for at least 3 months;

• HbA1c: 7.0%-10.0%.

Exclusion Criteria:

• Patients who were diagnosed with T1D, gestational diabetes or other specific types of diabetes.

• Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state;

• Patients with severe cardiac, hepatic, renal or general diseases;

• Subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.

• Absence of informed consent.